Peptidomimetics and small molecules as drug candidates

With its technology platform Peptides-to-Drugs (P2D) the biotechnology company pursued disease indications for which limited, inadequate, or no treatment options exist, most notably within the ophthalmology, oncology and inflammatory therapeutic areas.